Skip to content
Clinical Trials – home
Therapeutic area

Congenital, familial and genetic disorders – page 38

  • 796 clinical trials
  • 308 recruiting
  • 374 conditions
  • 27 countries

Conditions in this area

374 conditions with trials, the busiest first

Clinical trials in Congenital, familial and genetic disorders

796 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

796 clinical trials

Hereditary angioedema

Not recruiting

Study on NTLA-2002 for Treating Hereditary Angioedema in Patients: Evaluating the Effects of Ziclumeran and Lonvoguran

Registered drug
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Lonvoguran
  • Sponsor:Intellia Therapeutics Inc.

Hereditary angioedema

Not recruiting

Study of Deucrictibant Extended-Release Tablets for Prevention of Hereditary Angioedema Attacks in Adults and Adolescents

Registered drug
Countries:BulgariaBulgaria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Deucrictibant
  • Sponsor:Pharvaris Netherlands B.V.

Study of Ruxolitinib with Brentuximab or Pembrolizumab for Patients with Relapsed or Refractory Classical Hodgkin Lymphoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Brentuximab Vedotin
  • Sponsor:Universita Degli Studi Di Perugia

Arginase deficiency

Not recruiting

Title: Safety and effectiveness study of pegzilarginase weekly injections in children under 2 years old with Arginase 1 Deficiency

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:PEGZILARGINASE
  • Sponsor:Immedica Pharma AB

Prader-Willi syndrome

Not recruiting

Long-Term Study on Oxytocin for Children with Prader-Willi Syndrome Up to Age 4

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Oxytocin
  • Sponsor:Centre Hospitalier Universitaire De Toulouse

Study on the Effects and Safety of JR-141 and Idursulfase for Patients with Hunter Syndrome

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Idursulfase
  • Sponsor:Jcr Pharmaceuticals Co. Ltd.

Angelman's syndrome

Not recruiting

Study on the Effects of GTX-102 for Children with Angelman Syndrome

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:APAZUNERSEN
  • Sponsor:Ultragenyx Pharmaceutical Inc.

Noonan syndrome+2

Not recruiting

Study of Vosoritide for Children with Turner Syndrome, Short Stature Homeobox-Containing Gene Deficiency, and Noonan Syndrome Not Responding to Growth Hormone

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Vosoritide
  • Sponsor:Biomarin Pharmaceutical Inc.

Study on the Effectiveness and Safety of Venglustat for Adults and Children with Gaucher Disease Type 3

Registered drug
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Imiglucerase
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Adrenoleukodystrophy+1

Not recruiting

Study on Pramipexole for Treating Restless Legs in Women with X-linked Adrenoleukodystrophy

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Pramipexole Dihydrochloride Monohydrate
  • Sponsor:Amsterdam UMC Stichting

Study on the Safety and Effects of Saracatinib for Patients with Fibrodysplasia Ossificans Progressiva (FOP)

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:SARACATINIB
  • Sponsor:Amsterdam UMC Stichting
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Nusinersen
  • Sponsor:Biogen Idec Research Limited

Substances studied in this area

The therapies tested most often in Congenital, familial and genetic disorders trials.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.